You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 264 No. 1, July 4, 1990 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorials
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (14)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

How to Evaluate Drugs

Cost-effectiveness Analysis

J.Robert Beck, MD

JAMA. 1990;264(1):83-84.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The merchandisers of new pharmaceuticals have three principal features to consider when promoting a new drug: (1) Is it more effective than a competitor against the condition being treated? (2) Is it less costly? (3) Does it exhibit fewer side effects? With the costs of drug development, approval, and marketing continually increasing,1 it is rare to find a new medication that is less expensive than its predecessors. Advertisements in this and similar journals trumpet increased efficacy as the easiest concept to grasp in choosing among new drugs. Unfortunately for the manufacturers, not all new preparations can demonstrate increased potency, enhanced bioavailability, or better clinical results. In some recent cases, fewer adverse reactions are the distinguishing features of newer products.

How do you sell a medication that might be more costly, just as effective, and have fewer side effects? Cost-effectiveness analysis offers an answer. This technology compares the health effects . . . [Full Text PDF of this Article]


Author Affiliations

From the Biomedical Information Communication Center and the Department of Clinical Pathology, Oregon Health Sciences University, Portland.


Footnotes

The author consults for Pharmacon International, a consulting firm that offers decision support services to the pharmaceutical industry.

Reprint requests to Biomedical Information Communication Center, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd, Portland, OR 97201-3098 (Dr Beck).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.